Noninvasix is a pioneering brand that offers a groundbreaking solution for non-invasively and continuously measuring central venous saturation. With their patented optoacoustic platform technology, Noninvasix is set to revolutionize the field by monitoring central venous oxygenation, a crucial indicator of the severity of sepsis and septic shock. By integrating Noninvasix into the workflow of intensive care units (ICUs), clinicians will be able to swiftly and accurately diagnose critically ill patients and tailor treatments to enhance outcomes.

The potential applications of Noninvasix's technology extend beyond sepsis, encompassing medical scenarios like fetal monitoring, neonatal care, traumatic brain injury, blood loss, and anemia, where tissue hypoxia is present. With sepsis posing a significant risk to patient health and imposing substantial healthcare costs, Noninvasix is on a mission to transform patient care, save lives, and reduce expenses. Please note that Noninvasix's optoacoustic technology is currently awaiting FDA approval and is not currently available in the United States